Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 28 of 28 entries
Sorted by: Best Match Show Resources per page
Provider Attitudes, Organizational Readiness for Change, and Uptake of Research Supported Treatment.

Research on social work practice

Bornheimer LA, Acri M, Parchment T, McKay MM.
PMID: 32863681
Res Soc Work Pract. 2019 Jul 01;29(5):584-589. doi: 10.1177/1049731518770278. Epub 2018 Apr 18.

PURPOSE: As implementation and evaluation of research supported treatment (RST) expands across diverse mental health settings, it is essential to understand the facilitators and inhibitors of uptake. The current study examined the relationships between organizational readiness for change, attitudes...

Cite
Bornheimer LA, Acri M, Parchment T, et al. Provider Attitudes, Organizational Readiness for Change, and Uptake of Research Supported Treatment. Res Soc Work Pract. 2018;29(5):584-589doi: 10.1177/1049731518770278.
Bornheimer, L. A., Acri, M., Parchment, T., & McKay, M. M. (2019). Provider Attitudes, Organizational Readiness for Change, and Uptake of Research Supported Treatment. Research on social work practice, 29(5), 584-589. https://doi.org/10.1177/1049731518770278
Bornheimer, Lindsay A, et al. "Provider Attitudes, Organizational Readiness for Change, and Uptake of Research Supported Treatment." Research on social work practice vol. 29,5 (2019): 584-589. doi: https://doi.org/10.1177/1049731518770278
Bornheimer LA, Acri M, Parchment T, McKay MM. Provider Attitudes, Organizational Readiness for Change, and Uptake of Research Supported Treatment. Res Soc Work Pract. 2019 Jul 01;29(5):584-589. doi: 10.1177/1049731518770278. Epub 2018 Apr 18. PMID: 32863681; PMCID: PMC7450898.
Copy Download .nbib Format: NLM
Building the Science to Guide Nursing Administration and Leadership Decision Making.

The Journal of nursing administration

Joseph ML, Nelson-Brantley HV, Caramanica L, Lyman B, Frank B, Hand MW, Parchment J, Ward DM, Weatherford B, Chipps E.
PMID: 34897205
J Nurs Adm. 2022 Jan 01;52(1):19-26. doi: 10.1097/NNA.0000000000001098.

OBJECTIVE: The aim of this study was to identify the challenges, barriers, and solutions for conducting nursing administration and leadership science (NALS) research.BACKGROUND: Evidence from leadership science should be at the forefront of nurse leaders' decision making. Yet, challenges...

Cite
Joseph ML, Nelson-Brantley HV, Caramanica L, et al. Building the Science to Guide Nursing Administration and Leadership Decision Making. J Nurs Adm. 2022;52(1):19-26doi: 10.1097/NNA.0000000000001098.
Joseph, M. L., Nelson-Brantley, H. V., Caramanica, L., Lyman, B., Frank, B., Hand, M. W., Parchment, J., Ward, D. M., Weatherford, B., & Chipps, E. (2022). Building the Science to Guide Nursing Administration and Leadership Decision Making. The Journal of nursing administration, 52(1), 19-26. https://doi.org/10.1097/NNA.0000000000001098
Joseph, M Lindell, et al. "Building the Science to Guide Nursing Administration and Leadership Decision Making." The Journal of nursing administration vol. 52,1 (2022): 19-26. doi: https://doi.org/10.1097/NNA.0000000000001098
Joseph ML, Nelson-Brantley HV, Caramanica L, Lyman B, Frank B, Hand MW, Parchment J, Ward DM, Weatherford B, Chipps E. Building the Science to Guide Nursing Administration and Leadership Decision Making. J Nurs Adm. 2022 Jan 01;52(1):19-26. doi: 10.1097/NNA.0000000000001098. PMID: 34897205.
Copy Download .nbib Format: NLM
Commentary: Back to the future: Failed mitral valve bioprosthesis in the setting of mitral annular calcification.

JTCVS techniques

Parchment N, Brescia AA, Ailawadi G.
PMID: 34977735
JTCVS Tech. 2021 Aug 06;10:269-270. doi: 10.1016/j.xjtc.2021.08.007. eCollection 2021 Dec.

No abstract available.

Cite
Parchment N, Brescia AA, Ailawadi G. Commentary: Back to the future: Failed mitral valve bioprosthesis in the setting of mitral annular calcification. JTCVS Tech. 2021;10:269-270doi: 10.1016/j.xjtc.2021.08.007.
Parchment, N., Brescia, A. A., & Ailawadi, G. (2021). Commentary: Back to the future: Failed mitral valve bioprosthesis in the setting of mitral annular calcification. JTCVS techniques, 10269-270. https://doi.org/10.1016/j.xjtc.2021.08.007
Parchment, Nathaniel, et al. "Commentary: Back to the future: Failed mitral valve bioprosthesis in the setting of mitral annular calcification." JTCVS techniques vol. 10 (2021): 269-270. doi: https://doi.org/10.1016/j.xjtc.2021.08.007
Parchment N, Brescia AA, Ailawadi G. Commentary: Back to the future: Failed mitral valve bioprosthesis in the setting of mitral annular calcification. JTCVS Tech. 2021 Aug 06;10:269-270. doi: 10.1016/j.xjtc.2021.08.007. eCollection 2021 Dec. PMID: 34977735; PMCID: PMC8691222.
Copy Download .nbib Format: NLM
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz R, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, Wilsker D, Kinders RJ, Parchment RE, Chen L, Chang TC, Das B, Mugundu G, Doroshow JH, Chen AP.
PMID: 33863809
Clin Cancer Res. 2021 Jul 15;27(14):3834-3844. doi: 10.1158/1078-0432.CCR-21-0329. Epub 2021 Apr 16.

PURPOSE: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report results for once-daily adavosertib.PATIENTS AND...

Cite
Takebe N, Naqash AR, O'Sullivan Coyne G, et al. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021;27(14):3834-3844doi: 10.1158/1078-0432.CCR-21-0329.
Takebe, N., Naqash, A. R., O'Sullivan Coyne, G., Kummar, S., Do, K., Bruns, A., Juwara, L., Zlott, J., Rubinstein, L., Piekarz, R., Sharon, E., Streicher, H., Mittra, A., Miller, S. B., Ji, J., Wilsker, D., Kinders, R. J., Parchment, R. E., Chen, L., Chang, T. C., Das, B., Mugundu, G., Doroshow, J. H., & Chen, A. P. (2021). Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3834-3844. https://doi.org/10.1158/1078-0432.CCR-21-0329
Takebe, Naoko, et al. "Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3834-3844. doi: https://doi.org/10.1158/1078-0432.CCR-21-0329
Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz R, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, Wilsker D, Kinders RJ, Parchment RE, Chen L, Chang TC, Das B, Mugundu G, Doroshow JH, Chen AP. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 15;27(14):3834-3844. doi: 10.1158/1078-0432.CCR-21-0329. Epub 2021 Apr 16. PMID: 33863809; PMCID: PMC8282703.
Copy Download .nbib Format: NLM
Showing 25 to 28 of 28 entries